Support for limited brain availability of tyrosine in patients with schizophrenia

International Journal of Neuropsychopharmacology

Volumn 9, Issue 2, 2006, Pages 247-255

  Bjerkenstedt, Lars ^a,e   Farde, Lars ^a   Terenius, Lars ^a   Edman, Gunnar ^b   Venizelos, Nikolaos ^c   Wiesel, Frits Axel ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e Psykiatri Centrum Karolinska   (Sweden)

Author keywords

Amino acid; Dopamine; Schizophrenia; Tyrosine transport

Indexed keywords

DOPAMINE; ESSENTIAL AMINO ACID; NEUROLEPTIC AGENT; NORADRENALIN; PHENYLALANINE; TYROSINE;

AMINO ACID BLOOD LEVEL; AMINO ACID BRAIN LEVEL; AMINO ACID TRANSPORT; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; BRAIN LEVEL; CEREBROSPINAL FLUID ANALYSIS; CHROMOSOME 12; CLINICAL TRIAL; COGNITION; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; DRUG MEGADOSE; DRUG TRANSPORT; FIBROBLAST; HUMAN; LEARNING; MEMORY; MONOTHERAPY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVIEW; SCHIZOPHRENIA;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; COGNITION; HUMANS; SCHIZOPHRENIA; TYROSINE;

EID: 32844464420     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705005638     Document Type: Review

References (84)

1. Abi-Dargham A, Kegeles LS, Martinez D, Innis RB, Lamelle M (2003). Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: results from a large cohort. European Neuropsychopharmacology 13, 459-468.
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, German JM, Lamelle M (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proceedings of the National Academy of Sciences USA 97, 7673-7675.
3. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Washington, DC: American Psychiatric Press.
4. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel FA (1985). Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. British Journal of Psychiatry 147, 276-282.
5. Bleuler E (1911). Dementia praecox oder die Gruppe der Schizophrenien. Leipzig: Deuticke.
6. Breier A (2001). Introduction: a new era in the pharmacotherapy of psychotic disorders. Journal of Clinical Psychiatry 62, 3-5.
7. Carlsson A (1978). Antipsychotic drugs, neurotransmitters, and schizophrenia. American Journal of Psychiatry 135, 50-54.
8. Crandall EA, Fernstrom JD (1983). Effect of experimental diabetes on the levels of aromatic and branched-chain amino acids in blood and brain. Diabetes 32, 222-230.
9. Deijen JB, Wientjes CJ, Vullinghs HF, Cloin PA, Langefeld JJ (1999). Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. Brain Research Bulletin 48, 203-209.
10. Deutsch S, Rosse RB, Schwartz BL, Banay-Schwartz M, McCarthy MF, Johri SK (1994). L-tyrosine pharmacotherapy of schizophrenia: preliminary data. Clinical Neuropharmacology 17, 53-62.
11. Diamond A (1994). Phenylalanine levels of 6-10 mg/dl may not be as benign as once thought. Acta Paediatrica 407, 89-91.
12. Dixit BN, Buckley JP (1967). Circadian changes in brain 5-hydroxytryptamine and plasma corticosterone in the rat. Life Sciences 6, 775-759.
13. During MJ, Acworth IN, Wurtman RJ (1988). Phenylalanine administration influences dopamine release in the rat's corpus striatum. Neuroscience Letters 93, 91-95.
14. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JCM, Breteler MMB (2002). Dietary intake of antioxidants and risk of Alzheimer disease. Journal of the American Medical Association 287, 3223-3229.
15. Eriksson T, Voog L, Wålinder J, Eriksson TE (1989). Diurnal rhythm in absolute and relative concentrations of large neutral amino acids in human plasma. Journal of Psychiatric Research 23, 241-249.
16. 11C]raclopride. Archives of General Psychiatry 47, 213-219.
17. Feighner JP, Robins E, Guze SB, Woodruff Jr. RA, Winokur G, Munoz R (1972). Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 26, 57-63.
18. Feigin RD, Klainer AS, Beisel WR (1968). Factors affecting circadian periodiocity of blood-amino acids. Metabolism 17, 764-775.
19. Fernstrom JD, Faller DV (1978). Neutral amino acids in the brain: changes in response to food ingestion. Journal of Neurochemistry 30, 1531-1538.
20. Flyckt L, Venizelos N, Edman G, Bjerkenstedt L, Hagenfeldt L, Wiesel FA (2001). Aberrant tyrosine transport across the cell membrane in patients with schizophrenia. Archives of General Psychiatry 58, 953-958.
21. Frankle WG, Lerma J, Laruelle M (2003). The synaptic hypothesis of schizophrenia. Neuron 39, 205-216.
22. Freinkel N, Mager M, Vinnick L (1968). Cyclicity in the interrelationships between plasma insulin and glucose during starvation in normal young men. Journal of Laboratory and Clinical Medicine 71, 171-178.
23. Gardiner RM (1990). Transport of amino acids across the blood-brain barrier: implications for treatment of maternal phenylketonuria. Journal of Inherited Metabolic Disease 13, 627-633.
24. Gerlach J, Lühdorf K (1975). The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. A double-blind cross-over trial with Madopar and placebo. Psychopharmacologia 44, 105-110.
25. Goldman-Rakic PS, Muly ECR, Williams GV (2000). D(1) receptors in prefrontal cells and circuits. Brain Research Reviews 31, 295-301.
26. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia. American Journal of Psychiatry 153, 321-330.
27. Griffiths P, Paterson L, Harview A (1995). Neuropsychological effects of subsequent exposure to phenylalanine in adolescents and young adults with early-treated phenylketonuria. Journal of Intellectual Disability Research 39, 365-372.
28. Growdon JH, Melamed E, Logue M, Hefti F, Wurtman RJ (1982). Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sciences 30, 827-832.
29. Hagenfeldt L, Venizelos N, Bjerkenstedt L, Wiesel FA (1987). Decreased tyrosine transport in schizophrenic patients. Life Sciences 41, 2749-2757.
30. Haracz JL (1982). The dopamine hypothesis: an overview of studies with schizophrenic patients. Schizophrenia Bulletin 8, 438-469.
31. Hyde R, Taylor PM, Hundal HS (2003). Amino acid transporters: roles in amino acid sensing and signalling in animal cells. Biochemical Journal 373, 1-18.
32. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998). Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). Journal of Biological Chemistry 273, 23629-23632.
33. Karlsson P, Farde L, Halldin C, Sedvall G (2002). PET study of D1 dopamine receptor binding in neuroleptic-naive patients with schizophrenia. American Journal of Psychiatry 159, 761-767.
34. Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS (1986). Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Annals of Neurology 20, 258-262.
35. 11C]raclopride study in healthy men. Neuropsychopharmacology 29, 427-432.
36. Lieberman AM (2001). Comprehensive Care of Schizophrenia. London: Martin Dunitz Ltd.
37. Lindström LH (1985). Low HVA and normal 5-HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology. Psychiatry Research 14, 265-273.
38. Los DA, Murata N (2000). Regulation of enzymatic activity and gene expression by membrane fluidity. Sci STKE 62, PE1.
39. Matthews JC, Andersen KJ (2002). Recent advances in amino acid transporters and excitatory amino acid receptors. Current Opinion in Clinical Nutrition and Metabolic Care 5, 77-84.
40. McTavish SFB, McPherson MH, Harmer CJ, Clark L, Sharp T, Goodwin GM, Cowen PJ (2001). Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. British Journal of Psychiatry 179, 356-360.
41. Meltzer HY (1995). Atypical antipsychotic drugs. In Bloom, FE, Kupfer, DJ (Eds.), Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press.
42. 11C]raclopride PET study. American Journal of Psychiatry 160, 1887-1889.
43. Myhrer T (2003). Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Research Reviews 41, 268-287.
44. Ness GC, Takahasi T, Lee YP (1969). Thyroid hormones on amino acids and protein metabolism. I. Concentration and composition of free amino acids in blood plasma of the rat. Journal of Affective Disorders 9, 223-229.
45. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634-636.
46. Owens DGC, Harrison-Read PE, Johnstone EC (1990). L-dopa in very impaired schizophrenic patients. Clinical Neuropharmacology 13 (Suppl. 2), 174-175.
47. Pardridge WM (1998). Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochemical Research 23, 635-644.
48. Pardridge WM, Oldendorf WH (1977). Transport of metabolic substrates through the blood-brain barrier. Journal of Neurochemistry 28, 5-12.
49. Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ (1999). Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. Journal of Clinical Investigation 103, 1169-1178.
50. Pineda M, Fernandez E, Torrents D, Estevez R, Lopez C, Camps M, Lloberas J, Zorzano A, Palacin M (1999). Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. Journal of Biological Chemistry 274, 19738-19744.
51. Prasad PD, Wang H, Huang W, Kekuda R, Rajan DP, Leibach FH, Ganapathy V (1999). Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transport function. Biochemical and Biophysical Research Communications 255, 283-288.
52. Ramchand CN, Feet M, Clark AE, Gliddon AE, Hemmings GP (1996). Decreased tyrosine transport in fibroblasts from schizophrenics: implications for membrane pathology. Prostaglandins, Leukotrienes and Essential Fatty Acids 55, 59-64.
53. Rebolledo OR, Mercer RG, Gagliarding JJ (1974). Circadian variability in the effect of two inhibitors of protein synthesis. International Journal of Chronobiology 2, 159-162.
54. Reveley MA, De Belleroche J, Recordati A, Hirsch SR (1987). Increased CSF amino acids and ventricular enlargement in schizophrenia: a preliminary study. Biological Psychiatry 22, 413-420.
55. Schaffer MH, Davis JM, Tamminga CA (1985). Apomorphine's antipsychotic activity. Archives of General Psychiatry 42, 927-928.
56. Seeman P, Lee T, Chau-Wong M, Wong K (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
57. +-independent neutral amino acid transporter with broad substrate selectivity. Journal of Biological Chemistry 274, 19745-19751.
58. Sharp T, Zetterström T, Ljungberg T, Ungerstedt U (1987). A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Research 401, 322-330.
59. Shurtleff D, Thomas JR, Schrot J, Kowalski K, Herford R (1994). Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacology, Biochemistry and Behavior 47, 935-941.
60. Simon ML, George R (1975). Diurnal variation in plasma corticosterone and growth hormones as correlated with regional variations in norepinepherine, dopamine and serotonin content of rat brain. Neuroendocrinology 17, 125-138.
61. Sugawara M, Nakanishi T, Fei YJ, Huang W, Ganapathy ME, Leibach FH, Ganapathy V (2000). Cloning of an amino acid transporter with functional characteristics and tissue expression pattern identical to that of system A. Journal of Biological Chemistry 275, 16473-16477.
62. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M (1995). Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]. Journal of Clinical Psychopharmacology 15, 11S-18S.
63. Svensson TH, Nomikos GG, Andersson JL (1993). Modulation of dopaminergic neurotransmission by 5-HT2 antagonism. In: Vanhouette PM, Saxena PR, Paoletti R, Brunello N, Jackson AS (Eds.), Serotonin: from Cell Biology to Pharmacology and Therapeutics. Dordrecht: Kluwer Academic Publishers.
64. Takanaga H, Tokuda N, Ohtsuki S, Hosoya K, Terasaki T (2002). ATA2 is predominantly expressed as system A at the blood-brain barrier and acts as brain-to-blood efflux transport for L-proline. Molecular Pharmacology 61, 1289-1296.
65. Tam SY, Roth RH (1997). Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? Biochemical Pharmacology 53, 441-453.
66. Tamminga CA, Schaffer MH, Smith RC, Davis JM (1978). Schizophrenic symptoms improve with apomorphine. Science 200, 567-568.
67. Tannenbaum GS, Martin JB (1976). Evidence for an endogenous ultradian rhythm governing growth hormone secretion in the rat. Endocrinology 98, 562-570.
68. Tuckwell HC, Koziol JA (1993). A meta-analysis of homovanillic acid concentrations in schizophrenia. International Journal of Neuroscience 73, 109-114.
69. van Kammen DP, Boronow JJ (1988). Dextro-amphetamine diminishes negative symptoms in schizophrenia. International Clinical Psychopharmacology 3, 111-121.
70. van Kammen DP, van Kammen WB, Mann LS, Seppala T, Linnoila M (1986). Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Archives of General Psychiatry 43, 978-983.
71. van Rossum JM (1966). The significance of dopamine-receptor blockade for the action of neuroleptic drugs. Archives Internationales de Pharmacodynamie et de Therapie 160, 492-494.
72. Wagner CA, Lang F, Broer S (2001). Function and structure of heterodimeric amino acid transporters. American Journal of Physiology and Cell Physiology 281, C1077-1093.
73. Wang H, Huang W, Sugawara M, Devoe LD, Leibach FH, Prasad PD, Ganapathy V (2000). Cloning and functional expression pf ATA1, a subtype of amino acid transporter A, from human placenta. Biochemical and Biophysical Research Communications 273, 1175-1179.
74. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 44, 660-669.
75. Weinberger DR, Berman KF, Illowsky BP (1988). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. III: a new cohort and evidence for a monoaminergic mechanism. Archives of General Psychiatry 45, 609-615.
76. Weinberger DR, Berman KF, Suddath R, Torrey EF (1992). Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of disconcordant monozygotic twins. American Journal of Psychiatry 149, 890-897.
77. Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ERB (1990). Neuropsychology of early-treated phenylketonuria: specific executive function deficits. Child Development 61, 1697-1713.
78. Wiesel FA, Andersson JLR, Westerberg G, Wieseigren IM, Bjerkenstedt L, Hagenfeldt L, Långström B (1999). Tyrosine transport is differently regulated in patients with schizophrenia. Schizophrenia Research 40, 37-42.
79. 11C]tyrosine and PET. Journal of Nuclear Medicine 32, 2043-2049.
80. Wiesel F-A, Edman G, Flyckt L, Eriksson Å, Nyman H, Venizelos N, Bjerkenstedt L (2005). Kinetics of tyrosine transport and cognitive functioning in schizophrenia. Schizophrenia Research 74, 81-89.
81. Wiesel FA, Venizelos N, Bjerkenstedt L, Hagenfeldt L (1994). Tyrosine transport in schizophrenia. Schizophrenia Research 13, 255-258.
82. Wik G, Wiesel F-A (1991). Regional brain glucose metabolism: correlations to biochemical measures andanxiety in patients with schizophrenia. Psychiatry Research: Neuroimaging 40, 101-114.
83. Wing JC, Sartorius N (1974). Measurement and Classification of Psychiatric Symptoms: an Instructional Manual for the PSE and Catego Program. Cambridge: Cambridge University Press.
84. Wurtman RJ, Rose CM, Chou C, Larin FF (1968). Daily rhythms in the concentration of various amino acids in human plasma. New England Journal of Medicine 279, 171-175.